Weight-Loss Drugs and Bone: Review Finds Evidence Too Thin to Judge

The blockbuster medications reshaping obesity care may be doing something far less celebrated inside the skeleton, and a new systematic review says nobody can yet say for sure. The review, published in Archives of Osteoporosis on 23 October 2026, examined the randomized evidence on how glucagon-like peptide-1 receptor agonists, or GLP-1 RAs, affect bone in adults with overweight or obesity. Its verdict is stark: the evidence is too sparse and too clinically heterogeneous to establish the skeletal effects of this drug class. Led by Cheng-Hao Lai and colleagues, the review identified just eight randomized controlled trials comprising 493 participants, and rated the certainty of evidence as very low for every agent examined.

The question matters because GLP-1 RAs, including semaglutide, liraglutide, exenatide and dulaglutide, are widely used for weight management, yet their skeletal effects have remained uncertain. The review set out to address that uncertainty using randomized evidence alone, focusing on dual-energy X-ray absorptiometry measurements of bone mineral density, or BMD, and on bone turnover markers.

The team searched PubMed, Embase, Cochrane CENTRAL and Google Scholar from January 2015 to July 2026, following PRISMA 2020 reporting standards under a prospectively registered protocol, INPLASY202630076. Eligible trials enrolled adults aged 18 or older with a mean baseline body mass index above 25 kg/m², compared a GLP-1 RA against placebo or another antidiabetic therapy for at least 12 weeks, and reported BMD assessed by DXA. Risk of bias was judged with the Cochrane Risk of Bias 2 tool and certainty with GRADE.

A methodological decision shapes everything that follows. Because the trials tested four pharmacologically distinct agents that differ substantially in weight-lowering potency, the authors pooled nothing, synthesizing results narratively and reporting each drug separately. The eight trials broke down unevenly: semaglutide and dulaglutide were each evaluated in a single trial, liraglutide in two, and exenatide in five. Only three trials were at low risk of bias; five raised some concerns, principally regarding the randomization process and selective reporting. No agent is supported by more than one trial at low risk of bias. Five of the eight trials enrolled adults with type 2 diabetes, including all four that randomized an insulin comparator arm; only three studied adults without diabetes, one of them defined by obesity alone.

The single semaglutide trial, Hansen 2024, with 64 participants and a low risk of bias, produced the largest weight loss of any trial, an estimated treatment difference of minus 6.8 kilograms versus placebo. It reported reduced lumbar spine BMD of minus 0.018 g/cm², with a p value of 0.007, reduced whole-body BMD of minus 0.02 g/cm², a 95 percent confidence interval of minus 0.03 to minus 0.01, and increased C-terminal telopeptide, or CTX, a marker of bone resorption, by 166.50 pg/mL, with a 95 percent confidence interval of 66.60 to 266.40. The trial with the most dramatic slimming thus showed both less mineral in the skeleton and more bone being broken down.

Liraglutide told a dose-dependent story. At the weight-management dose of 3.0 mg daily, in the only trial conducted in adults with obesity and without diabetes, Jensen 2024, which achieved minus 6.7 kilograms versus placebo, lumbar spine BMD fell by 0.019 g/cm², a 95 percent confidence interval of minus 0.034 to minus 0.004, and total hip BMD fell by 0.013 g/cm², a 95 percent confidence interval of minus 0.024 to minus 0.002. At the diabetes dose of 1.8 mg daily, Hygum 2020, with minus 3.8 kilograms, no site changed materially; lumbar spine BMD was essentially flat, at 0.00 g/cm² with a 95 percent confidence interval of minus 0.01 to 0.01.

Exenatide, the most-studied agent with five trials, delivered the messiest picture. Lumbar spine estimates ranged from a gain of 0.03 g/cm², a 95 percent confidence interval of 0.02 to 0.03, in Renyuan 2015, to a loss of 0.04 g/cm², a 95 percent confidence interval of minus 0.15 to 0.07, in Akyay 2023, with intervals wide enough to leave both benefit and harm on the table. Dulaglutide rests on a single trial. By study-level mean baseline body mass index, five trials lay in the obese range at or above 30 kg/m² and three in the overweight range of 25 to below 30 kg/m².

Certainty of evidence was very low for every agent under GRADE. Yet the authors highlight a convergence they argue deserves dedicated scrutiny rather than dismissal: the two trials producing the largest weight loss, one of semaglutide and one of liraglutide 3.0 mg, both reported reduced lumbar spine and total hip BMD at closely similar magnitudes of weight loss, and the semaglutide trial additionally reported increased bone resorption. Whether that pattern reflects the degree of weight reduction, the drugs themselves, or the populations studied cannot be resolved from the available data, and the reviewers are explicit that it warrants dedicated evaluation rather than extrapolation across the drug class.

The bottom line is a call for better trials, not a warning label. Each agent has been evaluated in at most five small trials, most conducted in adults with type 2 diabetes rather than in adults with obesity alone. The reviewers conclude that adequately powered, agent-specific randomized trials with fracture endpoints are required before anyone can say whether GLP-1 RAs strengthen, spare, or sap the bones of the millions now taking them. Until then, the skeletal ledger of the obesity-treatment era remains unwritten.

Subject of Research: Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity

Article Title: Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review

Article References: Lai, C.-H., Li, Y.-T., Wu, T.-S., & Wu, C.-T. (2026). Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review. Archives of Osteoporosis, 21(1), Article 148. https://doi.org/10.1007/s11657-026-01785-8

Image Credits: AI Generated

DOI: 10.1007/s11657-026-01785-8

Keywords: GLP-1 receptor agonists, bone mineral density, obesity, systematic review, semaglutide, liraglutide, exenatide, osteoporosis, randomized controlled trials, weight loss, Skeletal, effects